Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.84) by 13.1 percent. This is a 25.86 percent decrease over losses of $(0.58) per share from the same period last year.
Acrivon Therapeutics Q1 EPS $(0.73) Beats $(0.84) Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.